Exchange: NASDAQ·Updated 04:28 PM EDT
News
all
press releases
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotechnology stock tanks as the company refocuses resources on its PDS0301 metastatic colorectal cancer program.read more...
Benzinga
More News
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April
PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest...
MarketBeat
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of PDS Biotechnology in a research note on Wednesday...
MarketBeat
Why Is PDS Biotechnology Stock Gaining Wednesday?
PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.read more...
Benzinga
PDSB Stock Hits 37-Week High — Here’s The Latest On Its Therapy To Treat Metastatic Colorectal Cancer
The biotech firm said its Phase 2 trial of PDS01ADC showed a strong objective response rate and a 24-month survival rate.
Stocktwits
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval
Stocktwits
Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026
Stocktwits

Advertisement|Remove ads.